Pimavanserin 34 mg
2023H0014
Phase 2 small_molecule active
Quick answer
Pimavanserin 34 mg for Intermittent Explosive Disorder is a Phase 2 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ACADIA PHARMACEUTICALS INC
- Indication
- Intermittent Explosive Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active